MedImmune, a AstraZeneca (NYSE: AZN) business, today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE